[{"id":"efbe23b4-71d5-4ec8-b170-e888d946d4fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03784378","created_at":"2021-01-18T18:42:53.766Z","updated_at":"2024-07-02T16:36:40.405Z","phase":"Phase 1","brief_title":"Continued Access to RXDX-105","source_id_and_acronym":"NCT03784378","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e agerafenib (RXDX-105)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 12/14/2018","start_date":" 12/14/2018","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 09/30/2020","study_completion_date":" 09/30/2020","last_update_posted":"2020-10-05"},{"id":"d66ac5ba-366c-48cf-8572-6aa1136cef2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01877811","created_at":"2021-01-17T17:54:36.010Z","updated_at":"2024-07-02T16:37:00.182Z","phase":"Phase 1","brief_title":"Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors","source_id_and_acronym":"NCT01877811","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e agerafenib (RXDX-105)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2019-04-25"}]